The global in-vitro toxicology testing market size was estimated at USD 22.7 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 10.7% from 2021 to 2028. Significant advancements in toxicology science are one of the primary factors driving the market. Also, high costs associated with conventional animal tests and socio-ethical concerns associated with animal tests are anticipated to boost the growth of the market for in-vitro toxicology testing.
As in-vitro toxicology studies can help in minimizing liabilities related to late-stage failure in the drug discovery process, a high number of research studies and drug development programs for COVID-19 are expected to accelerate the market for in-vitro toxicology testing. More than 590 drugs for COVID-19 are in the development program as of November 2020. Such a high number of drug development programs is anticipated to boost the demand for in vitro toxicology testing services.
Significant advancements in in-vitro toxicology assays to evaluate drug product safety along with the assessment of the potential effect of pharmaceuticals on cells and tissues are anticipated to bolster revenue generation in the market. With an increase in the need for such assays, companies have broadened their portfolio to serve demand in the market for in-vitro toxicology testing.
Availability of different methods in biotechnology and bioinformatics division to carry out in-silico simulation on animal models is also attributive for influencing industry growth through to 2028. Moreover, the development of toxicology databases for in-silico analysis of different compounds is anticipated to fuel demand for in-vitro techniques thereby leading to sector progress.
Considerable government funding for research coupled with definite reimbursement policies to develop automated and technologically advanced equipment for laboratory analysis and ex-vivo studies is expected to enhance market stability. On the contrary, unavailability of immunity testing and immune stimulation in current in-vitro tests is expected to hamper the growth of this industry.
The cell culture technology dominated the market for in-vitro toxicology testing in 2020 with a revenue share of over 47.0%. It serves as an excellent model for examining toxic effects since it provides consistent samples and reproducible results, which enables early-stage detection of toxicity in the drug development process. Moreover, cell cultures are increasingly replacing animal testing, leading to its extensive application.
In recent years, 3D cell culture models have gained significant traction due to the advantages it offers. For instance, it supports tissue-specific function, differentiation, and increases cell proliferation. Moreover, researchers are keen to incorporate mammalian cell culturing for designing novel therapeutic approaches as they aid in effective cell function investigation along with the screening of new compounds
On the other hand, the OMICS technology segment is estimated to register the highest CAGR over the forecast period as it offers personalized toxicology data, thereby providing better insights and reducing variability in the procured data. OMICS technologies largely contribute to a deeper understanding of the toxicity of nano-sized materials such as metal, carbon, and metal oxide nanoparticles. This technology led to the identification of new targets and markers in nanotoxicology as well as the detection of adverse effects of low particle concentrations on cells.
The systemic toxicology segment dominated the market for in-vitro toxicology testing and accounted for the largest revenue share of over 68.0% in 2020. The development of multiple organ plates with simulated blood flow for assessing systemic toxicity drives the segment growth. Moreover, public and private organizations are taking initiatives for replacing animal testing with in-vitro techniques for acute systemic toxicity testing.
The dermal toxicity segment is estimated to witness significant growth over the forecast period. Toxicology assays for dermal toxicology have proven to be a simple, reliable, and cost-effective choice. Advancements pertaining to the tools for dermal toxicity and risk assessment are anticipated to drive the segment.
The presence of regulatory guidelines for cosmetic toxicity testing drives the demand for in-vitro testing methodologies. The availability of toxicity assays adhering to government guidelines further fuels the segment growth. For instance, the 3T3 Neutral Red Uptake Phototoxicity Assay-as described under OECD Test Guideline 432-is used to assess phototoxicity of test materials that are either topically applied to the skin or are systemically administered within the body.
The cellular assay segment dominated the market for in-vitro toxicology testing and accounted for the largest revenue share of 43.8% in 2020. This can be attributed to the wider availability of this technique for pharmacokinetic profiling of drug products. Moreover, several pharmaceutical and biotechnological companies are essentially dependent on cellular assays for toxicity screening in the early stages of drug development.
In-vitro cell viability assays offer several advantages, such as minimal cost, speed, and potential for automation. However, these assays pose several technical challenges and are yet to completely replace animal testing, thus posing challenges to their growth. On the other hand, the ex-vivo segment is expected to grow at a considerable rate over the forecast period.
Ex-vivo or small explant cultures enable drug screening experiments to be conducted in a sterile, controlled, and dynamic environment by maintaining the native architecture of the tissues. A major advantage of using the ex-vivo model is that it performs tests or detections outside the organism and hence does not raise ethical concerns of performing tests on living subjects.
The pharmaceutical industry segment dominated the market for in-vitro toxicology testing and accounted for the largest revenue share of over 40.0% in 2020. The high usage of toxicology testing in pharmacokinetic analysis of novel and generic modified pharmaceutical products results in the revenue growth of these toxicity testing assays. Moreover, the presence of several drug candidates in the pipeline is expected to drive the demand for in-vitro toxicology testing.
To comply with the changing regulatory guidelines for drug development, these assays are mainly used in three areas-ADME, safety pharmacology, and genotoxicity testing of drug candidates. In addition, the development of biologics and biosimilars has resulted in a higher penetration of toxicity tests based on in-vitro models.
The chemical industry is expected to register lucrative growth over the forecast period owing to ongoing advancements associated with toxicity profiling in this sector. Strategic implementation of these tools for informed and efficient safety assessment at all stages of product development is expected to drive the demand for in-vitro toxicology testing in the industry.
North America dominated the in-vitro toxicology testing market and accounted for the largest revenue share of over 47.0% in 2020 owing to an increased focus of government bodies for drug discovery, rise in healthcare expenditure, and presence of adequate infrastructure for growth and development of drug discovery technologies. Furthermore, strong regulatory guidelines pertaining to drug development and approval have boosted the adoption of services in the regional market for in-vitro toxicology testing.
Ongoing launches of biologics and biosimilar products by biopharmaceutical manufacturers in the U.S. further drive the demand for in-vitro toxicology testing. In addition, government agencies are involved in investment and funding initiatives for drug discovery. National Institutes of Health and Defense Advanced Research Projects Agency are among some of the agencies actively involved in generating funds for basic drug discovery research and improving the adoption of alternative modes of toxicology testing in the U.S.
However, in Asia Pacific, the market for in-vitro toxicology testing is estimated to register relatively faster gains over the next seven years due to enhancement in health care infrastructure and rise in government incentives for research in academic and private organizations in order to aid enhancement in technology.
This industry shows the presence of a number of sector participants due to which there is an intense internal rivalry to occupy revenue share. Market participants are involved in the development of software solutions in order to enhance in-silico simulation methods for toxicological profiling of different compounds.
Market entities are also engaged in expanding their presence by entering untapped regions and collaborating with smaller clinical research organizations operating in this market. For instance, in August 2019, Abbott signed an agreement with Intoximeters, which gave Intoximeters exclusive distribution rights to Abbott's SoToxa Mobile Test System, a handheld oral fluid solution for drugs and alcohol testing in the U.S. The product enables the testing of methamphetamine, benzodiazepines, amphetamine, cocaine, cannabis (THC), and opiates. Some of the prominent players in the in-vitro toxicology testing market include:
Merck KGaA
Charles River
Bio-Rad Laboratories, Inc.
Abbott
Thermo Fisher Scientific Inc.
Catalent, Inc.
GE Healthcare
Quest Diagnostics Incorporated
Eurofins Scientific
Laboratory Corporation of America Holdings
Evotec
Creative Bioarray
Gentronix
BioIVT
SGS SA
Agilent Technologies
Report Attribute |
Details |
Market size value in 2021 |
USD 25.2 billion |
Revenue forecast in 2028 |
USD 51.1 billion |
Growth Rate |
CAGR of 10.7% from 2021 to 2028 |
Base year for estimation |
2020 |
Historical data |
2018 - 2019 |
Forecast period |
2021 - 2028 |
Quantitative units |
Revenue in USD million and CAGR from 2021 to 2028 |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segment coverage |
Technology, application, method, end-use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East Africa |
Country scope |
U.S.; Canada; Germany; U.K.; China; Japan; Brazil; South Africa |
Key companies profiled |
Thermo Fisher Scientific; Agilent Technologies; Bio-Rad Laboratories; Danaher Corporation; Quest Diagnostics; Merck KGaA; Perkin Elmer, Inc.; Laboratory Corporation of America Holdings; Eurofins Scientific; Charles River Laboratories International, Inc.; Abbott; Catalent, Inc.; Evotec; SGS SA; GVK Biosciences; Gentronix; WuXi AppTec; MB Research Laboratories; BioIVT |
Customization scope |
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of the customization |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2028. For the purpose of this study, Grand View Research has segmented the global in-vitro toxicology testing market report on the basis of technology, method, application, end use, and region:
End-use Outlook (Revenue, USD Million, 2018 - 2028)
Pharmaceutical Industry
Cosmetics & Household Products
Academic Institutes and Research Laboratories
Diagnostics
Chemical Industry
Food Industry
Technology Outlook (Revenue, USD Million, 2018 - 2028)
Cell Culture Technology
High Throughput Technology
Molecular Imaging
OMICS Technology
Application Outlook (Revenue, USD Million, 2018 - 2028)
Systemic Toxicology
Dermal Toxicity
Endocrine Disruption
Occular Toxicity
Others
Method Outlook (Revenue, USD Million, 2018 - 2028)
Cellular Assay
Live Cells
High Throughput / High Content Screening
Molecular Imaging
Confocal Microscopy
Others
Others
Fixed Cells
Biochemical Assay
In-Silico
Ex-vivo
Regional Outlook (Revenue, USD Million, 2018 - 2028)
North America
U.S.
Canada
Europe
Germany
U.K.
Asia Pacific
Japan
China
Latin America
Brazil
Middle East Africa (MEA)
South Africa
b. The global in-vitro toxicology testing market size was estimated at USD 22.7 billion in 2020 and is expected to reach USD 25.2 billion in 2021.
b. The global in-vitro toxicology testing market is expected to grow at a compound annual growth rate of 10.7% from 2021 to 2028 to reach USD 51.1 billion by 2028.
b. Cell culture technology dominated the in-vitro toxicology testing market with a share of 47.86% in 2020 as it serves as an excellent model for examining toxic effects since it provides consistent samples and reproducible results.
b. Some key players operating in the in-vitro toxicology testing market include Merck KGaA; Charles River; Bio-Rad Laboratories, Inc.; Abbott; Thermo Fisher Scientific Inc.; Catalent, Inc.; GE Healthcare; Quest Diagnostics Incorporated; Eurofins Scientific; Laboratory Corporation of America Holdings; Evotec; Creative Bioarray; Gentronix; BioIVT; SGS SA; and Agilent Technologies.
b. Key factors that are driving the in-vitro toxicology testing market growth include the rise in government funding for toxicology research, opposition to animal testing, and ongoing developments to advance toxicology research.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.